[go: up one dir, main page]

WO2008138658A3 - Composés pharmaceutiques comprenant des oligonucléotides abasiques - Google Patents

Composés pharmaceutiques comprenant des oligonucléotides abasiques Download PDF

Info

Publication number
WO2008138658A3
WO2008138658A3 PCT/EP2008/052956 EP2008052956W WO2008138658A3 WO 2008138658 A3 WO2008138658 A3 WO 2008138658A3 EP 2008052956 W EP2008052956 W EP 2008052956W WO 2008138658 A3 WO2008138658 A3 WO 2008138658A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compounds
abasic oligonucleotides
abasic
oligonucleotides
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/052956
Other languages
English (en)
Other versions
WO2008138658A2 (fr
Inventor
Hermann Wagner
Tobias Haas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Priority to EP08717702A priority Critical patent/EP2167662A2/fr
Publication of WO2008138658A2 publication Critical patent/WO2008138658A2/fr
Publication of WO2008138658A3 publication Critical patent/WO2008138658A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des composés qui peuvent moduler l'activité de récepteur de type Toll (TLR).
PCT/EP2008/052956 2007-05-14 2008-03-12 Composés pharmaceutiques comprenant des oligonucléotides abasiques Ceased WO2008138658A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08717702A EP2167662A2 (fr) 2007-05-14 2008-03-12 Composés pharmaceutiques comprenant des oligonucléotides abasiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108181.4 2007-05-14
EP07108181 2007-05-14

Publications (2)

Publication Number Publication Date
WO2008138658A2 WO2008138658A2 (fr) 2008-11-20
WO2008138658A3 true WO2008138658A3 (fr) 2009-04-23

Family

ID=39420344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/052956 Ceased WO2008138658A2 (fr) 2007-05-14 2008-03-12 Composés pharmaceutiques comprenant des oligonucléotides abasiques

Country Status (2)

Country Link
EP (1) EP2167662A2 (fr)
WO (1) WO2008138658A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US11471522B2 (en) * 2017-03-24 2022-10-18 BioNTech SE Methods and compositions for stimulating immune response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042018A2 (fr) * 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
WO2006080946A2 (fr) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
WO2006116458A2 (fr) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Analogues d'oligoribonucleotides modifies presentant une activite d'immunostimulation amelioree

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042018A2 (fr) * 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
WO2006080946A2 (fr) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
WO2006116458A2 (fr) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Analogues d'oligoribonucleotides modifies presentant une activite d'immunostimulation amelioree

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAILLET ET AL: "Deoxyribosylurea and deoxyribosylformamide oligonucleotides", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 36, no. 49, 4 December 1995 (1995-12-04), pages 8981 - 8984, XP005250039, ISSN: 0040-4039 *
BARRAT FRANCK J ET AL: "Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 202, no. 8, 1 October 2005 (2005-10-01), pages 1131 - 1139, XP002380606, ISSN: 0022-1007 *
EGAN W ET AL: "ABASIC OLIGODEOXYRIBONUCLEOSIDE PHOSPHOROTHIOATES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS-1 HIV-1 PHOSPHOROTHIOATE INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE AND INTERACTIONS WITH SYRIAN HAMSTER FIBROBLAST V79 CELLS", NUCLEOSIDES & NUCLEOTIDES, MARCEL DEKKER, INC, US, vol. 10, no. 1-3, 1 January 1991 (1991-01-01), pages 457 - 460, XP008101193, ISSN: 0732-8311 *
HAAS T ET AL: "The DNA Sugar Backbone 2' Deoxyribose Determines Toll-like Receptor 9 Activation", IMMUNITY, CELL PRESS, US, vol. 28, no. 3, 14 March 2008 (2008-03-14), pages 315 - 323, XP008101246, ISSN: 1074-7613 *
WAGNER ET AL: "The sweetness of the DNA backbone drives Toll-like receptor 9", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), pages 396 - 400, XP023612036, ISSN: 0952-7915, [retrieved on 20080730] *

Also Published As

Publication number Publication date
WO2008138658A2 (fr) 2008-11-20
EP2167662A2 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
EP1934239B8 (fr) Composes d'oligonucleotides de regulation immune (iro) permettant de moduler une reponse immune fondee sur un recepteur de type toll
WO2009156462A3 (fr) Composés organiques
WO2009152356A3 (fr) Composés et compositions utiles pour le traitement de la malaria
WO2011133876A3 (fr) Oligonucléotides comprenant des nucléosides acycliques et abasiques, et analogues
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2010006237A3 (fr) Oligonucléotides de phosphorothioate ou phosphorothiotes non nucléosidiques en tant qu'agents d’administration pour des agents d'arni
SI2132209T1 (sl) Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7)
WO2008083248A3 (fr) Analogues de cyclopamine
IL205671A0 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
BR112012000885A2 (pt) composições de fosfito estáveis hidroliticamente.
WO2008059370A3 (fr) Composés bicyclocarboxyamides substitués
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
WO2007138282A3 (fr) Nouveaux composés
WO2010129918A8 (fr) Promédicaments à base de triptolide
ZA201006227B (en) Pharmaceutical compositions having desirable bioavailability
WO2010054286A3 (fr) Composés d'hydroxyphénylamine substitués
WO2010089327A3 (fr) Dérivés d'indole en tant qu'agents anti-cancéreux
WO2008050199A3 (fr) Composés de phénylméthyl bicyclocarboxyamide substitués
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique
WO2009124962A3 (fr) Sulfonamides
WO2010054757A8 (fr) Combinaisons d'agents actifs présentant des propriétés insecticides et acaricides
WO2009149921A8 (fr) Inhibition de hrp-3 à l'aide d'oligonucléotides modifiés
CL2007003875A1 (es) Compuestos derivados de amidas del acido 3-amino tetrahidrofurano-3-carboxilico; procedimiento de preparacion de dichos compuestos.
BRPI0815713A2 (pt) Formulações lipossômicas de compostos de ácido borônico.
EP2300363A4 (fr) Synthèse facilitée par le brome de composés de fluoro-soufre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08717702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008717702

Country of ref document: EP